Non-Hodgkin Lymphoma | Specialty

Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

November 6th 2020

Choosing the Optimal Frontline Approach for Low-Grade Follicular Lymphoma

November 4th 2020

Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.

Making Progress Against Relapsed/ Refractory DLBCL Without CAR T

November 3rd 2020

A panel of lymphoma experts discuss several novel agents for relapsed/ refractory diffuse large B-cell lymphoma, some of which have been recently approved.

Off-the-Shelf CAR T-Cell Product CTX110 Shows Early Activity in Relapsed/Refractory CD19+ B-Cell Malignancies

October 23rd 2020

The investigational wholly-owned allogeneic CAR T-cell therapy CTX110 demonstrated dose-dependent efficacy and responses in patients with relapsed/refractory CD19-positive B-cell malignancies.

Copanlisib/Rituximab Prolongs PFS in Relapsed Indolent Non-Hodgkin Lymphoma

October 15th 2020

Copanlisib in combination with rituximab prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.

Mogamulizumab Significantly Boosts Outcomes in CTCL With Blood Involvement

October 13th 2020

Higher levels of blood tumor involvement were linked with more favorable outcomes in patients who received treatment with mogamulizumab compared with vorinostat in patients with 2 types of cutaneous T-cell lymphoma.

Dr. Martin on the Need for Head-to-Head Comparisons of BTK Inhibitors in MCL

October 12th 2020

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Expert Perspectives in the Evolving Treatment Landscape for Follicular Lymphoma

October 12th 2020

Experts provide their perspectives on the evolving treatment landscape for patients with follicular lymphoma.

Lancet Oncology Data Reinforce Regulatory Approvals of Tazemetostat in Sarcoma, Follicular Lymphoma

October 9th 2020

Tazemetostat demonstrated durable responses and sustained safety in patients with epithelioid sarcoma and relapsed/refractory follicular lymphoma.

Current and Emerging Treatments in Follicular Lymphoma

October 9th 2020

Although the majority of patients with follicular lymphoma have a life expectancy similar to that of the general population, predicting which patients will relapse and finding therapies that provide durable responses in the relapsed or refractory setting remains an ongoing challenge.

Sequencing Challenges Arise Amid New Approvals in DLBCL Paradigm

October 5th 2020

Andrew M. Evens, DO, MSc, discusses the approval of 3 new regimens and how they have reformed the treatment paradigm of relapsed/refractory diffuse-large B-cell lymphoma.

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

September 30th 2020

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

Dr. Pagel on Determining Treatment Based on Genetic Risk in Double- and Triple-Hit Lymphoma

September 29th 2020

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.

Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma

September 29th 2020

Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

September 29th 2020

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

Dr. Skarbnik on the Approval of Tazemetostat in Relapsed/Refractory Follicular Lymphoma

September 28th 2020

Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.

Dr. Batlevi on the Role of Active Surveillance in Advanced-Stage Follicular Lymphoma

September 28th 2020

Connie L. Batlevi, MD, PhD, discusses the role of active surveillance in advanced​-stage follicular lymphoma. 

Dr. Burke on Risk Stratification Strategies in Follicular Lymphoma

September 28th 2020

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma. 

Precision Medicine Picks up Pace Across Oncology

September 28th 2020

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

Precision Medicine Challenges Deepen in DLBCL As Subtypes Emerge

September 28th 2020

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.